AMENDMENTS

IN THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claims 1, 8, 9, 12-17, and 39-48 are pending in this Application.

Claims 2-7, 10-11, and 18-38 were previously canceled.

Claims 24-30 are withdrawn from consideration but are subject to rejoinder.

Claims 1, 9, 12, 13, and 40-43 are currently amended.

Claims 8, 14-17, 39, and 44-48 were previously presented.

1. (**currently amended**) A compound represented by formula **I**,



I

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof, and wherein,

each W is CR^1;

each R^1 is independently selected from -H and -A-R^7; provided one of R^1 is -A-R^7 and is located at the 5-position of the indolinone ring, wherein, only for said -A-R^7, R^7 must be a piperidin-4-yl, and where the nitrogen of the piperidin-4-yl of -A-R^7 is optionally substituted with one group selected from alkyl, ~~aryl,~~ arylalkyl, ~~heterocylylalkyl,~~ a monocyclic heteroalicyclicalkyl, ~~heterocylyl, acyl,~~ and sulfonyl[[,]];

A is NH;

L is NR^3;

Q is C;

R^2 and R^3 are each -H;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl ~~$-R^7$~~; or

R^4 and R^5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15};

R^6 is selected from -H, and C_{1-8}alkyl~~, arylC$_{1-8}$alkyl, heterocyclylC$_{1-8}$alkyl, aryl, and heterocyclyl~~;

R^7, for other than R^7 in –A-R^7, is selected from -H, and C_{1-8}alkyl~~, arylC$_{1-8}$alkyl, heterocyclylC$_{1-8}$alkyl, aryl, heterocyclyl; provided that there are at least two carbons between any heteroatom of R^7 and either nitrogen to which R^2 and R^3 are attached~~;[[or]]

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or [[and]]C_{1-8}alkyl;

X is selected from one of the following [[six]]formulae:






wherein m is zero to five, n is zero to three, and *Z* is CR^{10};

R^{10} is selected from -H, halogen, trihalomethyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7;

K is O; and

each R^{15} is independently selected from -H, halogen, $-OR^6$, and C_{1-8}alkyl ~~$-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7~~.

Claims 2-7 **(previously canceled)**

8. **(previously presented)** The compound according to claim 1, wherein X is



;

m is 0 to 3, and R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1\text{-}2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and $-C_{1\text{-}8}$alkyl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. **(currently amended)** A compound of formula **II**:



II

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A is NH;

R^7, in $-A-R^7$, is piperidin-4-yl and is located on the 5-position of the indolinone ring; wherein the ring nitrogen of R^7 is substituted with a group R^{12}; and

R^{12} is selected from a) -H, b) $C_{1\text{-}8}$alkyl, c) $-SO_2R^6$, d) $-SO_2NR^6R^7$, e) $-CO_2R^6$, f) $-C(O)NR^6R^7$, and g) $-C(O)R^7$; and where the $C_{1\text{-}8}$alkyl in b) is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, ~~heterocylylalkyl, heterocyclyl,~~ a monocyclic heteroalicyclic, alkoxy, ~~substituted alkoxy,~~ amino, alkylamino, and dialkylamino~~, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino~~;

R^6 is selected from -H and C_{1-8}alkyl;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl~~-R^7~~; or

R^4 and R^5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15};

R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and C_{1-8}alkyl;

m is 0 to 3;

R^7, for other than R^7 in A-R^7, is selected from -H, and C_{1-8}alkyl, ~~arylC_{1-8}alkyl, heterocyclylC_{1-8}alkyl, and heterocyclyl~~;

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or [[and]]C_{1-8}alkyl; and

each R^{15} is independently selected from -H, halogen, ~~$-OR^6$, and C_{1-8}alkyl $-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and $-R^7$~~.

Claims 10-11 **(previously canceled)**

12. **(currently amended)** A compound according to formula **III**.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R^{12} is a C_{1-4}alkylene;

R^{13} is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and ~~an~~ a monocyclic heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R^{12} which is directly attached to the ring nitrogen of the piperidine in formula III;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl ~~$-R^7$~~; or

R^4 and R^5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15};

R^6 is selected from -H and C_{1-8}alkyl;

R^7 is selected from -H, and C_{1-8}alkyl, ~~arylC$_{1-8}$alkyl, heterocyclylC$_{1-8}$alkyl, aryl, and heterocyclyl~~;

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or [[and]]C_{1-8}alkyl;

R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and C_{1-8}alkyl;

m is 0 to 3; and

each R^{15} is independently selected from -H, halogen, $-OR^6$, and C_{1-8}alkyl ~~$-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7~~.

13. **(currently amended)** A compound according to formula **IIIa**,



IIIa

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein R^{12} is a C_{2-4}alkylene;

R^{13} is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group and ~~an~~ a monocyclic heteroalicyclic;

R^{10} is selected from -H, halogen, perfluoroalkyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N{=}CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$;

R^4 and R^5 are each independently selected from -H, halogen, and C_{1-4}alkyl; or R^4 and R^5 combined are a phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl, ~~aryl, arylalkyl, heterocyclylalkyl, heterocyclyl,~~ alkoxy, ~~substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl,~~ and halogen~~, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, carbamyl, and acylamino~~;

m is 0-3;

R^6 is selected from -H and C_{1-8}alkyl~~, said C_{1-8}alkyl substituted with at least one of $-CO_2H$ and $-CO_2C_{1-8}$alkyl~~;

R^7 is selected from -H, and C_{1-8}alkyl~~, arylC_{1-8}alkyl, heterocyclylC_{1-8}alkyl, aryl, and heterocyclyl~~; and

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or [[and]]C_{1-8}alkyl.

14. **(previously presented)** The compound according to claim 13, wherein R^{12} is an ethylene; R^{10} is halogen; R^4 and R^5 are each independently selected from -H, halogen, and C_{1-2}alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

15. **(previously presented)** The compound according to claim 14, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and C_{1-2}alkyl; and m is 1-3; or a single stereoisomer, a single geometric

isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(previously presented)** The compound according to claim 15, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and $-CH_3$; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

17. **(previously presented)** The compound according to claim 16, wherein R^{10} is fluorine; R^4 and R^5 are each independently selected from –H and $–CH_3$; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

Claims 18-38 **(previously canceled)**

39. **(previously presented)** The compound according to claim 17, selected from:

49	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
51	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
58	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
70	(3*Z*)-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
78	(3*Z*)-3-[(4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
82	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one;
83	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one;
84	(3*Z*)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl}amino)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
85	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one;
106	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
107	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one; and

113	(3*Z*)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

40. **(currently amended)** The Compound of Claim 9 selected from

22	(3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2*H*-indol-2-one;
28	2-(2-{2-[(*Z*)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}(phenyl)methyl]-1*H*-imidazol-4-yl}ethyl)-1*H*-isoindole-1,3(2*H*)-dione;
30	(3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one;
81	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2*H*-indol-2-one; and
93	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2*H*-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

41. **(currently amended)** The compound of Claim 12 selected from

~~1~~	~~(3*Z*)-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-5-{[1-(phenylmethyl)pyrrolidin-3-yl]amino}-1,3-dihydro-2*H*-indol-2-one;~~
6	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
12	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
13	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
~~14~~	~~(3*Z*)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;~~
~~28~~	~~2-(2-{2-[(*Z*)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}(phenyl)methyl]-1*H*-imidazol-4-yl}ethyl)-1*H*-isoindole-1,3(2*H*)-dione;~~
50	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
52	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
57	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
59	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
63	(3*Z*)-3-[(3-fluoro-4-methylphenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
64	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1*H*-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
67	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;

69	(3*Z*)-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
77	(3*Z*)-3-[(4-methyl-1*H*-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
86	(3*Z*)-3-[1*H*-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
88	ethyl 2-{(*Z*)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]methyl}-4-methyl-1*H*-imidazole-5-carboxylate;
94	(3*Z*)-3-[1*H*-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
95	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
96	(3*Z*)-3-[(3-fluorophenyl)(4-phenyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one; and
97	(3*Z*)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

42. **(currently amended)** The compound of Claim 13 selected from

3	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1*H*-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
4	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1*H*-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
5	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{[5-(methyloxy)-1*H*-benzimidazol-2-yl][4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one;
7	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
8	(3*Z*)-3-{1*H*-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
9	(3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
11	(3*Z*)-3-[(4-aminophenyl)(1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
15	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one;
16	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
17	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
18	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
19	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;

21	(3*Z*)-3-[(3-aminophenyl)(1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
23	3-((*Z*)-1*H*-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene}methyl)benzenecarboximidamide;
24	(3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
26	(3*Z*)-3-{1*H*-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
27	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
29	(3*Z*)-3-[1*H*-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
38	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
39	(3*Z*)-3-{1*H*-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
42	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
45	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
46	(3*Z*)-3-[1*H*-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
47	(3*Z*)-3-[1*H*-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
55	(3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
56	(3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
60	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one;
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
62	(3*Z*)-3-[(3,5-difluorophenyl)(5-fluoro-1*H*-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
65	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
71	(3*Z*)-3-{1*H*-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
72	(3*Z*)-3-[(5-chloro-1*H*-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
89	(3*Z*)-3-[1*H*-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
90	(3*Z*)-3-{1*H*-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;
92	(3*Z*)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one;

100	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
101	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{(4-methyl-1*H*-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2*H*-indol-2-one;
103	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
108	(3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one;
114	(3*Z*)-3-[(3-trifluoromethylphenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
115	(3*Z*)-3-[(3-trifluoromethylphenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;
116	(3*Z*)-3-[(2,4-dichloro-5-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one; and
117	(3*Z*)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one;

where the compound is optionally as a pharmaceutically acceptable salt thereof.

43. (**currently amended**) The compound of Claim 16 selected from

40	(3*Z*)-3-[(3-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
41	(3*Z*)-3-[(3-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
~~42~~	~~(3*Z*) 3 [(1*H* benzimidazol 2 yl(3,5 difluorophenyl)methylidene] 5 ({1 [2 (methyloxy)ethyl]piperidin 4 yl}amino) 1,3 dihydro 2*H* indol 2 one~~
48	(3*Z*)-3-[(3-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
53	(3*Z*)-3-[(3-chloro-4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
54	(3*Z*)-3-[(3,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
66	(3*Z*)-3-[(4-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
73	(3*Z*)-3-[(3,5-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
74	(3*Z*)-3-[(3,5-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
75	(3*Z*)-3-[(3,5-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
76	(3*Z*)-3-[(3,5-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
79	(3*Z*)-3-[(3,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
80	(3*Z*)-3-[(3-chloro-4-fluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one

91	(3*Z*)-3-[(4-chlorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one
102	(3*Z*)-3-[(4-chlorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
104	(3*Z*)-3-[(3,4-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
105	(3*Z*)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
109	(3*Z*)-3-[(2,3-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
110	(3*Z*)-3-[(2,3-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
111	(3*Z*)-3-[(2,4-difluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
112	(3*Z*)-3-[(2,4-difluorophenyl)(1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one
118	(3*Z*)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one

where the compound is optionally as a pharmaceutically acceptable salt thereof.

44. **(previously presented)** The compound of Claim 39 named (3*Z*)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

45. **(previously presented)** The compound of Claim 39 named (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

46. **(previously presented)** The Compound of Claim 1 selected from (3*Z*)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2*H*-indol-2-one and (3*Z*)-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one; or a single geometric isomer thereof, optionally as a pharmaceutically acceptable salt thereof.

47. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1, 9, 12, 13, 39, 40, 41, 42, 43, or 46 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where

the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

48. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 44 or 45, where the compound is optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.